An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy

NCT00033189 | Completed Phase 2

• 1 other identifier: CNMC0301
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 2

Brief Summary

This study will help to determine the safety and efficacy of the nutritional supplement Coenzyme Q10 when added to steroids as a treatment for Duchenne muscular dystrophy (DMD). Boys with DMD who are enrolled in this study will should be on a stable dose of steroids for at least six months, and will remain on their usual dose throughout the study. They will complete two screening visits within a one-week period, and if enrolled will then have their strength tested monthly for three months before beginning therapy with Coenzyme Q10. Once Coenzyme Q10 therapy is started, participants will have their strength tested monthly for six months. Following the six month treatment period, participants will be given the option to remain on Coenzyme Q10 until the study is completed.

Conditions

Muscular Dystrophy, Duchenne

Keywords

duchenne; dystrophy; DMD; clinical trial; CINRG

Interventions

Coenzyme Q10 DRUG

Eligibility Criteria

• Age: 5 Years - 11 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Age: 5 - 11 years old
• Ambulant
• Diagnosis of DMD confirmed by at least one the following:
• Positive X-linked family history for typical Duchenne muscular dystrophy in older male relatives (onset by age 5 yr., wheelchair-bound by age 12 yr.) OR
• Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical Duchenne dystrophy OR
• Gene deletion test positive (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical Duchenne dystrophy.
• On Glucocorticosteroids: Children must be on a steady dose of prednisone or deflazacort, on any schedule (Daily, alternate days, 10 days on, 10 days off or twice a week), for the last 6 months before starting the clinical trial. Dose of steroid or schedule cannot be altered during the study.
• Evidence of muscle weakness by MRC score or clinical functional evaluation
• Ability to provide reproducible repeat QMT bicep score within 10% of first assessment score.
• Ability to swallow tablets

You may not qualify if:

• Symptomatic DMD carrier
• Previous (6 months or less) or current use of Coenzyme Q10 (for DMD or any other disease)
• Use of carnitine, other amino acids, creatine, glutamine, or any herbal medicines within the last 3 months.
• History of significant concomitant illness or significant impairment of renal or hepatic function.

Sponsors & Collaborators

• Cooperative International Neuromuscular Research Group: lead

Study Sites (2)

Children's National Medical Center

Washington D.C., District of Columbia, 20010, United States

Location

Washington University-St. Louis

St Louis, Missouri, 63110, United States

Location

MeSH Terms

Conditions

Muscular Dystrophy, Duchenne

Interventions

coenzyme Q10

Condition Hierarchy (Ancestors)

Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NETWORK

Study Record Dates

• First Submitted: April 8, 2002
• First Posted: April 9, 2002
• Study Start: September 1, 2001
• Study Completion: January 1, 2005
• Last Updated: November 16, 2010

Record last verified: 2010-11

Locations

US (2)